Valuation: NGL Fine-Chem Limited

Market Cap 15.76B 166M 149M 137M 124M 232M 236M 1.63B 655M 8.29B 623M 610M 26.15B P/E 2025
32.6x
P/E 2026 26.6x
Enterprise Value 16.54B 174M 156M 144M 130M 243M 248M 1.71B 687M 8.7B 654M 640M 27.44B EV / Sales 2025
1.9x
EV / Sales 2026 2.71x
Free-Float
27.51%
Yield 2025
0.16%
Yield 2026 0.08%
1 day-1.86%
1 week-3.52%
1 month-12.29%
3 months-21.87%
6 months+13.65%
Current year+81.05%
1 week 2,550
Extreme 2550
2,702.95
1 month 2,467.6
Extreme 2467.6
3,251
Current year 1,322
Extreme 1322
3,595
1 year 1,261
Extreme 1261
3,595
3 years 962.7
Extreme 962.7
3,595
5 years 962.7
Extreme 962.7
3,595
10 years 220
Extreme 220
3,789.45
Manager TitleAgeSince
Chief Executive Officer 61 2015-06-29
Director of Finance/CFO 50 2009-08-27
Compliance Officer - 2026-02-02
Director TitleAgeSince
Chairman 61 2011-08-11
Director/Board Member 50 2010-07-20
Director/Board Member - 2015-08-04
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-3.52%+69.72%+41.51% 166M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.69%+4.96%+48.90%+80.26% 426.21B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.43%

Financials

2025 2026
Net sales 3.68B 38.78M 34.73M 31.95M 28.95M 54.11M 55.13M 381M 153M 1.94B 146M 142M 6.11B 5.01B 52.76M 47.25M 43.46M 39.38M 73.61M 74.99M 518M 208M 2.64B 198M 194M 8.31B
Net income 211M 2.22M 1.99M 1.83M 1.66M 3.1M 3.16M 21.86M 8.77M 111M 8.35M 8.17M 350M 481M 5.07M 4.54M 4.18M 3.78M 7.07M 7.2M 49.79M 19.99M 253M 19.02M 18.62M 798M
Net Debt 116M 1.22M 1.09M 1M 910K 1.7M 1.73M 11.97M 4.81M 60.86M 4.57M 4.48M 192M 783M 8.24M 7.38M 6.79M 6.15M 11.5M 11.72M 81M 32.51M 412M 30.94M 30.28M 1.3B
Projected Income Statement - Annual - NGL Fine-Chem Limited
Logo NGL Fine-Chem Limited
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Employees
498
Date Price Change Volume
26-10-30 ₹2,551.05 -1.86% 100
26-10-29 ₹2,599.50 -1.01% 149
26-10-28 ₹2,625.95 +0.04% 102
26-10-27 ₹2,625.00 +0.21% 17
26-10-26 ₹2,619.45 -0.94% 320
  1. Stock Market
  2. Stocks
  3. NGLFINE Stock